AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05403658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care is delivered similarly across the 2 clinical sites. Obesity management is offered by multidisciplinary teams that include clinicians with advanced expertise in pediatrics, nutrition, mental health, physical activity/exercise, and behavior change. Interventions are tailored to families' readiness, capabilities, and motivation to make healthy lifestyle and behavioral changes.
Study NCT04993586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 2 mg of AG0302-COVID19 three times at 2-week intervals
Study NCT04993586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 4 mg of AG0302-COVID19 twice at 4-week intervals
Study NCT04993586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intramuscular Injection
Description: Vaccination 8 mg of AG0302-COVID19 twice at 4-week intervals
Study NCT04993586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intradermal Injection
Description: Vaccination 1 mg of AG0302-COVID19 three times at 2-week intervals
Study NCT04993586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG0302-COVID19 for Intradermal Injection
Description: Vaccination 1 mg of AG0302-COVID19 twice at 4-week intervals
Study NCT05818124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Four molnupiravir 200 mg capsules (800 mg total dose) taken twice daily by mouth.
Study NCT06098573 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information condition
Description: Participants in the DUIC Information condition will receive a Qualtrics link with six infographics created to educate about DUIC. Four infographics were retrieved from government websites, one was provided by a non-profit (i.e., Arrive Alive Drive Sober), and the research team created the final one. After reviewing each infographic, participants will respond to a few questions about the infographic. Questions asked to the DUIC Info Control will obtain data related to: seeing the infographic before, perceptions on the infographic content, aspects they liked/disliked, and likelihood to share with their peers. All items will be treated as research data.
Study NCT06098573 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No contact
Description: Participants in the passive control will receive no contact until the three and six-month follow-ups.
Study NCT05185622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vamorolone
Description: Oral administration of vamorolone for 12 weeks.
Study NCT06028113 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE 2.0
Description: Overview of content and strategies: 1) Education on stage of development specific to infant feeding, sleep and infant regulation, attunement to cues; 2) Attunement to cues: reinforcing and modeling accurate discernment \& responsiveness to cues; 3) Infant Soothing and Regulation: Coaching alternative strategies for soothing that feeding for non-hungry, fussy infants; 4) Routines \& Strategies: Promoting developmental activities during wake windows and longer consolidated sleep at night as the infant grows.
Study NCT05818124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo molnupiravir
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.
Study NCT05818124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo molnupiravir
Description: Four placebo capsules matched to molnupiravir taken twice daily by mouth.
Study NCT05818124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oseltamivir
Description: Placebo capsule matched to oseltamivir taken twice daily by mouth.
Study NCT05818124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Description: One capsule of oseltamivir 75 mg taken twice daily by mouth.
Study NCT05926050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment (CopaPrime+ (USANA Health Sciences)
Description: Participants received and consumed 2 treatment tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained extracts of Bacopa monnieri (150 mg), Coffea arabica (50 mg), and Panax quinquefolius L. (50 mg)
Study NCT05818124 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
Study NCT05286619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
Study NCT05286619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
Study NCT05926050 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received and consumed 2 placebo tablets immediately following baseline testing, and one hour prior to post-treatment testing. Each tablet contained microcrystalline cellulose. The size, shape and appearance of the placebo tablet was identical to the treatment tablet.
Study NCT05286619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
Study NCT05286619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
Study NCT05400564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: This intervention includes access to the Family Check-Up app and telehealth coaching provided by trained mental health providers. Parents can contact their Coach as often as they like and a minimum of 3 coaching sessions will be scheduled.
Study NCT06560736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Show Me FIRST coping skills intervention
Description: Show Me FIRST is a flexible, transdiagnostic intervention organized around well-tested principles of youth psychotherapeutic change.
Study NCT04912518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine (DEX)
Description: The patient began to inject DEX intravenously as soon as he enrolled. This study started with the maximum maintenance dose allowed by the label (0.7μg/kg/h). With reference to previous studies, we set 3 pump injection gradients within the range of 0.2-0.7μg/kg/h (0.2μg/kg/h, 0.45μg/kg/h, 0.7μg/kg/h), and based on the patient's heart rate , systolic blood pressure and RASS sedation score to adjust.
Study NCT04912518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: The patient began intravenous injection of normal saline immediately after enrollment. The administration method and dosage adjustment of normal saline are the same as DEX.
Study NCT05040932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH004
Description: IV infusion once every 3 weeks (Q3W).
Study NCT06643871 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted physical activity program involving connected bikes
Description: The treatment being studied involves a program (DYNAMO-PSY) of adapted physical activity with an enriched environment (connected bike, visualized and experienced routes in virtual reality) and is supervised, comprising (on average) two sessions per week, a total of 20 sessions to be completed over a maximum of 15 weeks. Each session will last 60 minutes and will be supervised by a case manager. They will be composed of a warm up, session on the bike (around 30 minutes of bicycling) and stretching. They will take place in an adequate room in the clinical research department of Saint Anne Hospital. The usual hygienic-dietetic care is not modified by the study and consists of the care proposed to patients of the GHU Paris Psychiatry and Neuroscience who have had a first psychotic episode and are treated primarily with medication: clinical and biological monitoring, dietary consultations, therapeutic education group concerning diet and lifestyle.
Study NCT05605249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cue X
Description: The Cue X movement training module includes several games that can be performed in someone's home environment. The games are designed based on known physiotherapy guidelines and evidence for improving motor symptoms for people with PD and delivered in AR. Some of the games also have integrated cueing to allow people with more severe mobility impairments to participate. Feedback of performance can be given using the movement data of the AR headsets.
Study NCT05301127 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal-epidural device
Description: received combined spinal-epidural-general anesthesia.
Study NCT05702450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study NCT05702450 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CM310
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study NCT06548438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the bladder performed with PDD tecnique and Hexvix
Description: For the execution of PDD cystoscopy in blue light, it is necessary to use the study drug (Hexvix) which, after intravesical instillation, causes an accumulation of porphyrins in the lesions of the bladder wall at the intracellular level. The intracellular porphyrins are photoactive fluorescent compounds that emit red light when excited with blue light. Consequently, the preneoplastic and neoplastic lesions will emit a red luminescence against a blue background, allowing for better visualisation and subsequent resection.
Study NCT06194838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ossur Power Knee
Description: Newest version of the commercially-available powered knee developed by Ossur.
Study NCT06194838 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reboocon Intuy Knee
Description: Commercially-available powered knee developed by Reboocon.
Study NCT05757050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Re-Focus Verum Tablets
Description: The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
Study NCT05757050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Re-Focus Verum Tablets
Description: The active intervention contains Scutellaria baicalensis (400 mg) and Crataegus (40 mg) and is in the form of a chewable tablet with a blood-orange flavour
Study NCT05757050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Re-Focus Placebo Tablets
Description: The placebo will be a matched control.
Study NCT05757050 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Re-Focus Placebo Tablets
Description: The placebo will be a matched control.
Study NCT05102019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 1: treatment with Neovasc Reducer
Description: Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
Study NCT05102019 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 2 (control): Implantation procedure with no device implanted
Description: No device is implanted
Study NCT05102019 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Arm 3 (unblinded, non-randomized): Single arm registry
Description: Neovasc reducer is an implantable device being evaluated for the alleviation of refractory angina symptoms
Study NCT05736471 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computational dissociation of the causes of cognitive rigidity in depression
Description: involves a single testing session with surveys and tasks relevant to the experiment involving behavioral tasks and self-report questions through an online crowd-sourcing platform
Study NCT06351280 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardised Physiotherapy Plan
Description: Single session of coached deep breathing and coughing exercises. 10 supervised slow flow deep breaths to total lung capacity with a 3-5 second end inspiratory hold completed with 2 end inspiratory sniffs. 2-3 supported coughs or huffs. Repeated for another set. Patients instructed to perform independently hourly. Assisted ambulation according to the following protocol:~* Stage 1 of 2 minutes.~* Stage 2 of 0-1 minute.~* Stage 3 of 1 - 3 minutes.~* Stage 4 of 3 - 6 minutes.~* Stage 5 of 6 - 10 minutes.~* Stage 6 of 10 - 15 minutes.~* Stage 7 > 15 minutes. Total session time is the accumulative work time.
Study NCT05159128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75105186
Description: JNJ-75105186 will be administered orally in Part 1 and 2.
Study NCT05818124 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
Study NCT05818124 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Influenza A Virus
Description: Influenza A challenge virus given once by intranasal administration at an inoculum concentration of between approximately 5 and 7 Log10 tissue culture infective dose 50% (TCID50/mL).
Study NCT05549063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility and Stability Exercise
Description: Mobility and stability exercises
Study NCT05549063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Exercise
Description: Balance and reaching exercise
Study NCT05437172 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: injectable platelet rich fibrin with demineralized dentin graft
Description: after atraumatic extraction, collection of whole venous blood (9 ml) in sterile vacutainer tubes will be done without anticoagulant added, vacutainer tubes will be then placed in a centrifugal machine at 700 revolutions per minute (rpm) for 3 min with a tube filled with water to maintain the balance during the centrifuging process. ADDG particles prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze. Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
Study NCT05437172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: demineralized dentin graft
Description: after atraumatic extraction, ADDG particles will be prepared by demineralization of tooth particles in 0.6N hydrochloric acid for 30 min to achieve demineralization then washed twice in saline and dried with sterile gauze.~Graft particles will be loaded at the defect site to restore ridge form, large metal condenser was used to adapt the graft to the defect and stabilizing the graft with sutures.
Study NCT04691752 — intervention group
Intervention type: OTHER
Intervention: Audit
Description: Audit from clinical records
Study NCT04859673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: radial extracorpeal shock wave
Description: Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
Study NCT04859673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radial extracorpeal shock wave
Description: Swiss DolorClast® Master - Shockwave Therapy System will be used to apply the radial extracorporeal shock wave. It consists of master console, Evo Blue hand-piece, 15mm and 36mm interchangeable contact heads (applicators), contact gel, cart, and external compressor
Study NCT05545007 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiosurgery (HSRS)
Description: HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
Study NCT05545007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery (HSRS)
Description: HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.
Study NCT05545007 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain metastases surgical resection
Description: Complete surgical resection of brain lesions with adeguate margins.
Study NCT05545007 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Brain metastases surgical resection
Description: Complete surgical resection of brain lesions with adeguate margins.
Study NCT05159128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to JNJ-75105186 will be administered orally in Parts 1 and 2.
Study NCT06411405 — intervention group
Intervention type: OTHER
Intervention: Maternal medical history
Description: See above; multiple factors to be collected broadly grouped into maternal medical, obstetric, and sociodemographic/lifestyle factors.
Study NCT06556771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gongs mobilization + conventional physical therapy
Description: 3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks
Study NCT06556771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kaltenborn mobilization along with traction + conventional therapy
Description: 3 per week , mobilization for 5 minutes , exercise 3 sets for 10 repetitions for 4 consecutive weeks.
Study NCT06558331 — intervention group
Intervention type: OTHER
Intervention: Preoperative Quality of Recovery-15 (QoR-15T)
Description: The quality of recovery score (QoR)-15 questionnaire, preoperative
Study NCT06448637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Coated Balloon (DCB)
Description: Drug Coated Balloon (DCB) in patients with indication of Percutaneous Coronary Intervention (PCI)
Study NCT06448637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Stent (DES)
Description: Drug Eluting Stent (DES) in patients with indication of Percutaneous Coronary Intervention (PCI)
Study NCT04904484 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iZephyr hood
Description: Assessment of an aerosol containment device
Study NCT06558331 — intervention group
Intervention type: OTHER
Intervention: Postoperative 24th hour Quality of Recovery-15 (QoR-15T)
Description: The quality of recovery score (QoR)-15 questionnaire, postoperative 24th hour
Study NCT06416475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mankai supplementation
Description: The overall dose of the three Mankai duckweed beverages/day contains \~10 grams of dry matter.
Study NCT06416475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water consumption
Description: Water consumption
Study NCT06039514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GGTCA-AD mobile app
Description: The intervention will be done through an adaptation of the GGTCA app for teenagers: GGTCA-AD. This app is used to work on the dysfunctional beliefs that are associated with eating disorders. The app is made up of a series of levels comprising the topics that are normally worked on in cognitive behavior therapy (CBT) in relation to eating disorders. At each level, affirmations in the form of beliefs appear on the screen, and the person must accept them if they are functional, adaptive and positive; or reject them if they are dysfunctional, maladaptive and negative.
Study NCT06039514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GGNeutra mobile app
Description: the control group will complete another module belonging to the GGTUDE digital platform. Specifically, this app is called GGNEUTRA, and the statements that compose it are totally independent of the target of the study. The operation is similar, sentences appear in the center of the screen, but in this case, the person must accept those sentences that are true, for example: Madrid is the capital of Spain, by dragging it to the top of the screen; and reject those that are false, for example: Tokyo is the capital of Spain, by dragging it to the bottom of the screen.
Study NCT04788693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation of gait with motor imagery
Description: Physical rehabilitation of gait is a type of non-invasive treatment that seeks to change the way of performing a task or motor function (in this case, gait) through movement modification and corrected repeated practice, taking into account the alterations, limitations and considerations related to the disease suffered by the person. In this intervention, in addition to physical exercise to correct gait, mental exercises will be included in which the patient visualizes himself performing the exercises that he will then develop with the body.